Nkmax Co Ltd
182400
Company Profile
Business description
Nkmax Co Ltd engages in the development, manufacture, and sale of recombinant proteins and monoclonal antibodies. Its products include NK cells under NK Vue brand, recombinant proteins, and monoclonal antibodies. The firm provides prevention for diseases like Cancer, Aging and contagious diseases, Autoimmune diseases.
Contact
172 Dolma-ro, Bundang-gu, Gyeonggi-do
SNUH Health Care Innovation Park, 6th Floor
Seongnam-si13605
KORT: +82 3180178114
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
74
Stocks News & Analysis
stocks
Stellar growth from ASX retailer but markets still too optimistic
This Australian success story looks set to face profit margin compression from the scariest of competitors.
stocks
How to focus on the right things this reporting season
For individual investors, it is important to frame earnings season revelations in a long-term way.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,150.30 | 32.70 | 0.36% |
| CAC 40 | 7,753.42 | 54.90 | 0.71% |
| DAX 40 | 24,050.12 | 31.22 | -0.13% |
| Dow JONES (US) | 44,415.22 | 440.13 | 1.00% |
| FTSE 100 | 9,147.81 | 18.10 | 0.20% |
| HKSE | 24,969.68 | 62.87 | 0.25% |
| NASDAQ | 21,595.95 | 210.55 | 0.98% |
| Nikkei 225 | 42,718.17 | 897.69 | 2.15% |
| NZX 50 Index | 12,759.68 | 152.18 | -1.18% |
| S&P 500 | 6,426.87 | 53.42 | 0.84% |
| S&P/ASX 200 | 8,880.80 | 36.00 | 0.41% |
| SSE Composite Index | 3,665.92 | 18.37 | 0.50% |